UNASSIGNED: This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) @entity978 ( @entity978 ) given within its indication. From June 2011 to April 2015, ninety-five @entity1 with R/R @entity978 , who received BV in 20 centers from Greece, were analyzed. Their median age was 33  years, and 62% were males. Sixty-seven @entity1 received BV after autologous stem cell transplantation failure, whereas 28 @entity1 were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the @entity1 were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven @entity1 achieved an objective response: twenty-two (23%), a complete response (CR), and 35 @entity1 (37%), a partial, for an overall response rate of 60%. Twelve @entity1 (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5  months, median progression-free survival and overall survival were 8 and 26.5  months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P  =  .005). Bulky disease (P  =  .01) and response to BV (P  <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P  =  .04), bulky disease (P  =  .005), and B-symptoms (P  =  .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13  months. In conclusion, our data indicate that BV is an effective treatment for R/R @entity978 @entity1 even outside clinical trials. Whether BV can cure a fraction of @entity1 remains to be seen.

Brentuximab vedotin in relapsed/refractory XXXX . The Hellenic experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']
